Comparative Analysis of Orthosteric and Allosteric GLP-1R Agonists’ Effects on Insulin Secretion from Healthy, Diabetic, and Recovered INS-1E Pancreatic Beta Cells
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25126331 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Joshua Reed und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Life Science, Medical School, Swansea University, Singleton Park, Swansea SA2 8PP, UK. Hauptthemen laut MEDLINE: Insulin-Secreting Cells, Glucagon-Like Peptide-1 Receptor, Insulin Secretion, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Despite the availability of different treatments for type 2 diabetes (T2D), post-diagnosis complications remain prevalent; therefore, more effective treatments are desired. Glucagon-like peptide (GLP)-1-based drugs are currently used for T2D treatment. They act as orthosteric agonists for the GLP-1 receptor (GLP-1R). In this study, we analyzed in vitro how the GLP-1R orthosteric and allosteric agonists augment glucose-stimulated insulin secretion (GSIS) and intracellular cAMP production (GSICP) in INS-1E pancreatic beta cells under healthy, diabetic, and recovered states. The findings from this study suggest that allosteric agonists have a longer duration of action than orthosteric agonists. They also suggest that the GLP-1R agonists do not deplete intracellular insulin, indicating they can be a sustainable and safe treatment option for T2D. Importantly, this study demonstrates that the GLP-1R agonists variably augment GSIS through GSICP in healthy, diabetic, and recovered INS-1E cells. Furthermore, we find that INS-1E cells respond differentially to the GLP-1R agonists depending on both glucose concentration during and before treatment and/or whether the cells have been previously exposed to these drugs. In conclusion, the findings described in this manuscript will be useful in determining in vitro how pancreatic beta cells respond to T2D drug treatments in healthy, diabetic, and recovered states.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Life Science, Medical School, Swansea University, Singleton Park, Swansea SA2 8PP, UK.
ORCID-Profile: Venkateswarlu Kanamarlapudi
Zitieren
APA
Reed, J., Higginbotham, V., Bain, S., & Kanamarlapudi, V. (2024). Comparative Analysis of Orthosteric and Allosteric GLP-1R Agonists’ Effects on Insulin Secretion from Healthy, Diabetic, and Recovered INS-1E Pancreatic Beta Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25126331
Vancouver
Reed J, Higginbotham V, Bain S, Kanamarlapudi V. Comparative Analysis of Orthosteric and Allosteric GLP-1R Agonists’ Effects on Insulin Secretion from Healthy, Diabetic, and Recovered INS-1E Pancreatic Beta Cells. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25126331
BibTeX
@article{Reed2024,
author = {Reed, Joshua and Higginbotham, Victoria and Bain, Stephen and Kanamarlapudi, Venkateswarlu},
title = {Comparative Analysis of Orthosteric and Allosteric GLP-1R Agonists’ Effects on Insulin Secretion from Healthy, Diabetic, and Recovered INS-1E Pancreatic Beta Cells},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25126331}
}
EUVIMED